Frexalimab study validates PROMIS-Fatigue-MS-8a and MSIS-29v2 in relapsing multiple sclerosis patients
New tools reliably measure fatigue in multiple sclerosis
This Phase 2 trial assessed psychometric validation of PROMIS-Fatigue-MS-8a and MSIS-29v2 in adults with relapsing multiple sclerosis.
Two questionnaires accurately track fatigue in relapsing MS, offering a new way to measure treatment benefits in trials.
Oral cladribine reshapes CSF immune cell composition in relapsing multiple sclerosis
Cladribine therapy changes immune cells in fluid from the brain in a small MS study
This single-site phase IV clinical trial used single-cell sequencing on CSF and blood from 13 individuals with relapsing MS before and after…
Cladribine therapy reshapes immune cells in the brain's fluid by reducing harmful memory B cells while boosting protective Treg cells in mul…
Ponesimod Shows Sustained Efficacy and Safety in RMS Over 5 Years
Could Ponesimod Change the Game for Multiple Sclerosis Patients?
In a 5-year extension of the OPTIMUM study, ponesimod 20 mg maintained a lower ARR (0.143) compared to teriflunomide switchers (0.184).
After five years, nearly half of people taking ponesimod for multiple sclerosis had no relapses, offering more stable lives with fewer unexp…